Tandem Diabetes Care Announces Proposed Underwritten Public Offering of Common Stock, Series A Warrants and Series B Warrants
October 12 2017 - 4:01PM
Business Wire
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device
company and manufacturer of the only touchscreen insulin pumps
available in the United States, today announced that it is
proposing to offer and sell shares of its common stock, Series A
warrants and Series B warrants to purchase shares of its common
stock in an underwritten public offering. All of the shares of
common stock and warrants to be sold in the offering are being
offered by Tandem. The offering is subject to market conditions and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering. The
Company intends to use the net proceeds from the proposed offering
for working capital and other general corporate purposes.
Oppenheimer & Co. Inc. is acting as the sole book‐running
manager for the offering. National Securities Corporation, a wholly
owned subsidiary of National Holdings Corporation (NasdaqCM: NHLD),
is acting as a co-manager in connection with the offering.
This offering is being made pursuant to a shelf registration
statement on Form S-3 that was previously filed by Tandem with
the Securities and Exchange Commission and declared
effective on December 19, 2014. A preliminary prospectus
supplement and accompanying prospectus describing the terms of the
proposed offering will be filed with the Securities and Exchange
Commission and will form a part of the effective registration
statement. When available, copies of the preliminary prospectus
supplement and the accompanying prospectus relating to the
securities being offered may be obtained from: Oppenheimer &
Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad St.,
26th Floor, New York, NY 10004, by telephone at (212) 667-8563 or
by email at EquityProspectus@opco.com. Electronic copies of
the preliminary prospectus supplement and accompanying prospectus
will also be available on the Securities and Exchange Commission’s
website at www.sec.gov.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. The offering
will be made only by means of a prospectus that forms a part of the
registration statement.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach
to the design, development and commercialization of products for
people with diabetes who use insulin. Tandem manufactures and sells
the t:slim X2™ Insulin Pump, the only pump capable of remote
feature updates using a personal computer, now available with
Dexcom G5® Mobile continuous glucose monitoring (CGM) integration,
and the t:flex® Insulin Pump, the first pump designed for people
with greater insulin requirements. Tandem is based in San Diego,
California.
Follow Tandem Diabetes Care on Facebook at
www.facebook.com/TandemDiabetes.Follow Tandem Diabetes Care on
LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
t:flex and Tandem Diabetes Care are registered trademarks, and
t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom G5 is
a registered trademark of Dexcom, Inc.
Forward Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. These forward-looking statements include
statements regarding the Company’s expectations regarding the sales
of shares and warrants in the proposed offering and other
statements that are not purely statements of historical fact. Such
forward-looking statements are based on the Company’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results, and the timing of
events, may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including the uncertainties regarding market conditions
and the completion of the underwritten offering on the anticipated
terms or at all. Other risks and uncertainties are identified in
the Company’s most recent Annual Report on Form 10-K and Quarterly
Report on Form 10-Q, and other documents that the Company files
with the Securities and Exchange Commission including the
Registration Statement on Form S-3 (File No. 333-200686) for the
offering. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release. Unless otherwise required by applicable law or the
rules of the NASDAQ Stock Market, Tandem undertakes no obligation
to update or revise any forward-looking statement in this press
release because of new information, future events or other
factors.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171012006394/en/
for Tandem Diabetes CareMedia Contact:Steve
Sabicer714-907-6264ssabicer@thesabicergroup.comorInvestor
Contact:Susan Morrison858-366-6900
x7005smorrison@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Apr 2023 to Apr 2024